First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis
- DOI
- 10.21037/jtd.2019.07.45
- Published
- 2019-07
- Container
- Journal of Thoracic Disease
- Publisher
- AME Publishing Company
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.21037/jtd.2019.07.45,
title = {First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis},
author = {Tingting Liu and Silu Ding and Jun Dang and Hui Wang and Jun Chen and Guang Li},
year = {2019},
journal = {Journal of Thoracic Disease},
doi = {10.21037/jtd.2019.07.45},
url = {https://doi.org/10.21037/jtd.2019.07.45}
}RIS
TY - JOUR TI - First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis AU - Tingting Liu AU - Silu Ding AU - Jun Dang AU - Hui Wang AU - Jun Chen AU - Guang Li PY - 2019 JO - Journal of Thoracic Disease DO - 10.21037/jtd.2019.07.45 UR - https://doi.org/10.21037/jtd.2019.07.45 ER -
APA
Liu, T., Ding, S., Dang, J., Wang, H., Chen, J., & Li, G. (2019). First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis. Journal of Thoracic Disease. https://doi.org/10.21037/jtd.2019.07.45
Source records
- crossref · retrieved 2026-09-27T11:54:01.837Z